Orient EuroPharma , Ltd. Return on Equity

Orient EuroPharma , Ltd. (4120.TWO) currently reports a ROE of -10.3%. That is below the sector sector average of 11.64%. Use the charts on this page to explore Orient EuroPharma , Ltd.'s ROE history and peer comparisons.

Orient EuroPharma , Ltd.'s ROE of -10.3% is lower than the its sector sector average of 11.64%. That is roughly 188.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Orient EuroPharma , Ltd.'s current -10.3% should be judged against industry norms (sector average: 11.64%) and against 4120.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -10.3%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Orient EuroPharma , Ltd., and consider following 4120.TWO for alerts when major investors trade the stock.